Pharvaris (PHVS) Earnings Date & Reports

Key Takeaways

• Pharvaris (PHVS) is expected to report its third-quarter 2026 results on or around November 11, 2026, before the market open, with a conference call scheduled the following day.
• Wall Street consensus points to a net loss of roughly $0.82 per share, compared with a loss of $0.70 per share in the same period a year earlier.
• As a clinical-stage biopharmaceutical company, Pharvaris generates little or no product revenue, so investors will focus on trial progress, operating expenses, and cash runway rather than the top line.
• In its most recent report (the second quarter of 2026), the company posted a loss of $0.81 per share, wider than the roughly $0.74 consensus, and has beaten estimates in 3 of its last 8 quarters.
• Key watch items include updates on deucrictibant, its oral bradykinin B2 receptor antagonist for hereditary angioedema (HAE), and commentary on a cash position of roughly $364 million.
• For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, be sure to explore the additional pages for PHVS.
• Explore Trending AI Robots to discover AI-driven trading strategies and market insights.

Earnings Context and Why It Matters

Pharvaris is a clinical-stage biopharmaceutical company developing oral therapies for hereditary angioedema (HAE), a rare genetic condition that causes sudden, painful swelling episodes. Because the company has no approved product yet, its quarterly earnings are driven less by revenue and more by research and development (R&D) spending and clinical milestones. This report matters because it offers investors a gauge of how efficiently management is deploying its roughly $364 million cash balance while advancing deucrictibant through late-stage trials. After missing consensus in the second quarter, the third-quarter update will be closely watched for signals on trial timelines and capital needs.

Earnings Expectations

Analysts expect Pharvaris to report a net loss of approximately $0.82 per share for the third quarter of 2026, according to consensus estimates. That compares with a loss of $0.70 per share reported in the third quarter of 2025. Revenue expectations remain modest, with some consensus figures near $2.35 million, reflecting the company's pre-commercial status.

In its most recent quarter, Pharvaris reported a loss of $0.81 per share, missing the roughly $0.74 consensus estimate. The company has beaten consensus earnings per share (EPS) in 3 of its last 8 quarters, underscoring the volatility that can surround early-stage biotech results. Given the lack of meaningful revenue, investors will focus less on the headline EPS figure and more on clinical progress, spending discipline, and any update to the company's cash runway.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking clinical-stage names like Pharvaris, it can be a useful way to surface comparable opportunities and monitor shifting market conditions.

Market Reaction and Investor Sentiment

Sentiment heading into the report remains cautious. Pharvaris shares have climbed meaningfully over the past year, but the stock has historically shown sensitivity to earnings-day moves, and data suggests a negative post-earnings drift following its last release. With no product revenue to anchor the story, the market's reaction will likely hinge on qualitative updates: whether trial timelines remain on track, how R&D costs are trending, and whether management reaffirms its cash runway. A wider-than-expected loss alone may matter less than any change to the clinical narrative or capital outlook.

Forward Outlook and Key Factors to Monitor

Following this earnings event, investors should watch for updates on the advancement of deucrictibant across its HAE programs, particularly any shifts in late-stage trial timelines or regulatory milestones. Because the company is pre-revenue, the pace of clinical development is the single most important driver of long-term value.

Operating expenses and cash burn also deserve attention. Pharvaris held roughly $364 million in cash as of its most recent disclosures, which provides a meaningful runway, but any acceleration in R&D or administrative spending could reshape expectations for future financing needs. Commentary on capital allocation will help investors assess whether the company can fund its programs into pivotal readouts.

Finally, monitor broader biotech sentiment and any competitive developments in the HAE space, where new oral and injectable options continue to emerge. Changes in analyst estimates, trial enrollment updates, and partnership or financing announcements are all catalysts that could influence how the market interprets Pharvaris's progress in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations